iRhythm Technologies Faces Shareholder Lawsuit Over Misrepresentation of Zio AT Monitor
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: 4 day ago0mins
- Shareholder Lawsuit Investigation: Kuehn Law is investigating whether officers of iRhythm Technologies breached their fiduciary duties to shareholders, particularly regarding undisclosed information about the Zio AT monitor's intended use, potentially exposing shareholders to losses.
- Market Misrepresentation: Executives repeatedly touted the growth potential of the Zio AT as an innovative product, failing to clarify that it was a real-time monitor for high-risk patients, leading investors to misinterpret its premium pricing.
- Stock Price Impact: As a result of these misleading statements, iRhythm's stock traded at artificially inflated prices during relevant periods, which may result in financial losses for shareholders in the future.
- Urgency of Legal Action: Kuehn Law urges shareholders to contact them promptly to enforce their rights within a limited timeframe, emphasizing that shareholder voices are crucial for maintaining the integrity and fairness of financial markets.
IRTC.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on IRTC
Wall Street analysts forecast IRTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRTC is 219.62 USD with a low forecast of 185.00 USD and a high forecast of 244.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
12 Buy
2 Hold
0 Sell
Strong Buy
Current: 181.350
Low
185.00
Averages
219.62
High
244.00
Current: 181.350
Low
185.00
Averages
219.62
High
244.00
Morgan Stanley
Overweight
maintain
$195 -> $205
2025-12-02
Reason
Morgan Stanley
Price Target
$195 -> $205
2025-12-02
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on iRhythm to $205 from $195 and keeps an Overweight rating on the shares. Going into 2026, MedTech "looks well-positioned on several fronts" as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for "a solid industry setup," the analyst tells investors in a note for the group on the upcoming year.
Goldman Sachs
David Roman
Neutral
maintain
$180 -> $202
2025-11-03
Reason
Goldman Sachs
David Roman
Price Target
$180 -> $202
2025-11-03
maintain
Neutral
Reason
Goldman Sachs analyst David Roman raised the firm's price target on iRhythm to $202 from $180 and keeps a Neutral rating on the shares.
Truist
Richard Newitter
Buy
maintain
$205 -> $230
2025-11-02
Reason
Truist
Richard Newitter
Price Target
$205 -> $230
2025-11-02
maintain
Buy
Reason
Truist analyst Richard Newitter raised the firm's price target on iRhythm to $230 from $205 and keeps a Buy rating on the shares. The company delivered a clean Q3 beat and raise result fueled by core business strength, Zio AT adoption, and progress with innovative channel partners, the analyst tells investors in a research note. The increase in FY25 revenue guidance signals the management's confidence in broad portfolio momentum going forward, the firm added.
Oppenheimer
Oppenheimer
Outperform
maintain
$175 -> $225
2025-10-31
Reason
Oppenheimer
Oppenheimer
Price Target
$175 -> $225
2025-10-31
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on iRhythm to $225 from $175 and keeps an Outperform rating on the shares. The firm notes Q3 revenue came in at $193M, bucking the seasonal trend and ahead of its/consensus $184M/$185M estimates.
See All Ratings
About IRTC
iRhythm Technologies, Inc. is a digital health care company, which creates solutions that detect, predict, and prevent disease. The Company designs, develops, and commercializes device-based technology to provide ambulatory cardiac monitoring services. It offers three Zio System options: the Zio Monitor System, the Zio XT System, and the Zio AT System. It offers its Zio ambulatory cardiac monitoring services, including long-term continuous monitoring, short-term continuous monitoring, and mobile cardiac telemetry (MCT) monitoring services (Zio Services), using its Zio Systems. The Zio Monitor System is a prescription-only, remote ECG monitoring system that consists of a patch ECG monitor (the Zio Monitor patch) that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software (ZEUS) System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What fiduciary duties are officers of iRhythm Technologies accused of breaching?
How does shareholder participation enhance iRhythm's corporate governance and transparency?
How might the investigation impact iRhythm's stock price in the future?
What are the potential outcomes of the shareholder lawsuits against iRhythm?